Our World
Contact Us

Press Releases 2021

Biocon Biologics  /  Press Releases  /  Press Releases 2021

Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
  • Thu, 30-Dec-2021
  • Posted by: Biocon Biologics
No Comments

Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
  • Thu, 23-Dec-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
  • Wed, 01-Dec-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
  • Fri, 19-Nov-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
  • Tue, 16-Nov-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
  • Mon, 15-Nov-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
  • Thu, 04-Nov-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
  • Fri, 22-Oct-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
  • Thu, 21-Oct-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
  • Thu, 16-Sep-2021
  • Posted by: Biocon Biologics
No Comments
Report adverse events/side effects/product complaints and/or to submit medical inquiries for Biocon Biologics Limited & BBL Affiliate products.

* Cookie Policy | Privacy Policy | Terms of Use © 2025, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share
buy twitter followers - matadorbet güncel adres - onwin - onwin güncel adres - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler -

groepenkast

- takipcimx 1000 - buy facebook followers -

çekişmeli boşanma avukatı